February 15, 2008

Baxter Heparin Danger Extends Beyond Initial Lots

Posted at February 15, 2008 12:41 PM in .

Heparin deaths and allergic reactions appear to extend beyond the nine lots disclosed by Baxter a week ago according to a Wall Street Journal Report on Thursday February 14,2008. Heparin is used for a wide variety of medical procedures to prevent clotting such as kidney dialysis and open heart surgery. Baxter did not suspend sales of heparin because it markets about 50% of the heparin on the market and suspension of sales would cause a shortage. This decision was made in consultation with the U.S. Food and Drug Administration. Baxter confirmed to the Wall Street Journal that it gets the active pharmaceutical ingredient for heparin from a Chinese factory that had not been inspected. Our firm is investigating these cases and I expect that we will discover that again the FDA is understaffed and underfunded to protect the public from the danger of poor manufacturing practices in China.

Contact the Lawyers at Saunders & Walker about this for a free case evaluation -- Click Here

Trackback

You can ping this entry by using http://www.saundersblog.com/cgi-bin/mt/mt-tb.cgi/505 .

Comments

Post a comment










Remember personal info?